Archived Press Releases

2020

16/11/2020Successful friendly takeover bid by OncoDNA for IntegraGen shares
18/09/2020IntegraGen - 1st half 2020 results
09/07/2020Agreement on a friendly takeover bid by OncoDNA for IIntegraGen
03/04/2020IntegraGen - Annual results 2019
26/03/2020IntegraGen announces agreement with leading US cancer center to use MERCURY™
11/03/2020IntegraGen renews partnership agreement with Institut Pasteur
10/01/2020IntegraGen - 2019 sales and cash position

2019

23/09/2019IntegraGen - 1st half 2019 results
11/07/2019IntegraGen - Sales of €4.2m in the first half of 2019, up +151TP3Q
18/04/2019IntegraGen - Annual results 2018
05/03/2019IntegraGen and Advanced Biological Laboratories announce the signing of a global license agreement for the commercialization of the miRpredX™ assay.
09/01/2019IntegraGen - 2018 sales and cash position

2018

12/11/2018IntegraGen announces collaboration with Google Cloud to bring its large-scale sequencing data analysis tools to clinicians and researchers
20/09/2018IntegraGen - 1st half 2018 results
04/09/2018Publication of the results of the FIRE-3 study in Clinical Cancer Research, highlighting the potential of the miR-31-3p biomarker to select the treatment best suited to the genetic profile of patients with metastatic colorectal cancer.
31/07/2018GCS SeqOIA chooses IntegraGen to operate its sequencing platform as part of the France Genomic Medicine 2025 Plan
10/07/2018IntegraGen - Sales growth at June 30, 2018: +17%
23/04/2018IntegraGen obtains ISO 13485:2016 certification for the design, production and distribution of in vitro diagnostic kits
13/04/2018IntegraGen - 2017 annual results: sustained momentum in clinical genomics services and improved net income.
12/04/2018IntegraGen presents results of study on circulating microRNAs as predictive markers of treatment response at European Lung Cancer Conference 2018
14/02/2018IntegraGen and Twist Bioscience extend partnership with distribution agreement for genomic analysis tools, SIRIUS and MERCURY
25/01/2018IntegraGen joins forces with Twist Bioscience
18/01/2018IntegraGen launches two Big Data solutions for high-performance exploration of large-scale genomic data: SIRIUS™ and MERCURY™
09/01/2018IntegraGen - 2017 sales and cash position
09/01/2018IntegraGen and GoPath Laboratories announce the signature of a license agreement for the commercialization of the miR-31-3p test in North America.

2017

30/10/2017IntegraGen receives Galien MedStartUp award for its collaboration with The Solution Lab on ICE software
09/10/2017IntegraGen announces publication of miR-31-3p data at Oncotarget
28/09/2017IntegraGen - 1st half 2017 results
07/09/2017IntegraGen announces CE-IVD marking of miRpredX 31-3p kit
11/07/2017Continued strong growth in the first half of 2017
21/04/2017IntegraGen announces financial results for 2016
08/03/2017CERBA Laboratory and IntegraGen sign licensing agreement for miR-31-3p assay
03/02/2017IntegraGen - Successful completion of €3.7m capital increase
09/01/2017Sales 2016

2016

14/10/2016IntegraGen - 1st half 2016 results
10/10/2016IntegraGen presented new positive efficacy data for the miR-31-3p biomarker at the 2016 ESMO Congress
07/07/2016IntegraGen - Strong sales growth in the 1er half-year 2016
29/06/2016AP-HP and IntegraGen to develop a joint ultra-high-throughput sequencing platform
06/06/2016IntegraGen presents positive results at ASCO 2016 on miR-31-3p biomarker
08/04/2016IntegraGen announces financial results for 2015
14/01/2016Sales 2015

2015

02/12/2015IntegraGen announces collaboration with FIRE 3 investigators to validate hsa-miR-31-3p biomarker in metastatic colorectal cancer
17/11/2015Gustave Roussy and IntegraGen announce the completion of over a thousand analyses in less than eighteen months on their joint sequencing platform for clinical research.
02/10/2015IntegraGen - 1st half 2015 results
25/08/2015Results of Integragen's sequencing of 193 liver tumors identify a new virus involved in the development of liver cancer
10/07/2015IntegraGen - 1st half 2015 sales
08/07/2015AP-HP: Hôpital Européen Georges Pompidou and IntegraGen announce cooperation agreement 
07/07/2015IntegraGen : Issuance of new shares
01/06/2015At ASCO, IntegraGen announces positive results from two new studies on the role of the biomarker miR-31-3p
05/05/2015IntegraGen secures optional equity financing
10/04/2015IntegraGen: 12% sales growth in 2014
27/03/2015IntegraGen reaffirms its PEA-PME eligibility
24/03/2015Institut Pasteur joins forces with IntegraGen to strengthen its high throughput sequencing activities in microbiology
05/02/2015IntegraGen announces distribution agreement for its autism predisposition test
08/01/2015Annual review of the liquidity contract

2014

16/12/2014IntegraGen and PICCOLO trial investigators announce collaboration agreement to validate role of Hsa-miR-31-3p biomarker in metastatic colorectal cancer
02/12/2014IntegraGen awarded worldwide licensing rights for two molecular signatures in liver cancer.
07/10/2014IntegraGen - 1st half 2014 results
30/09/2014IntegraGen presents data at ESMO confirming that its microRNA biomarker is predictive of the effect of anti-EGFR treatment in patients with metastatic colorectal cancer
02/09/2014IntegraGen announces collaboration with the Intergroupe Francophone de Cancérologie Thoracique (IFCT) to explore the use of the miR-31-3p biomarker in non-small cell lung cancer
16/07/2014IntegraGen - 1st half 2014 results
23/06/2014IntegraGen, Gustave Roussy, Inserm and Sogeti High Tech announce the development of scientific software to help interpret genomic sequencing data and revolutionize cancer diagnostics
12/06/2014IntegraGen: Very successful capital increase
02/06/2014IntegraGen presents bio-marker data at ASCO to predict treatment effect in colorectal cancer patients
19/05/2014IntegraGen presents data from a new version of the ARISk® test at the 13th annual IMFAR conference
15/05/2014IntegraGen: Publication of a study demonstrating the correlation between progression-free survival of patients treated with anti-EGFR for metastatic colorectal cancer and the level of expression of the hsa-mi-31-3p biomarker in the tumor
11/04/2014IntegraGen - Annual results 2013
03/04/2014IntegraGen announces a collaboration agreement with Pfizer to evaluate the value of its molecular signature in hepatocellular carcinoma
24/03/2014IntegraGen and Gustave Roussy announce the creation of an ultra-high-throughput clinical sequencing unit 
21/02/2014IntegraGen announces publication of a study reconfirming the association of common genetic variants with autism
14/01/2014IntegraGen announces collaboration with New EPOC investigators to validate a biomarker in metastatic colorectal cancer
09/01/2014Annual review of the liquidity contract

2013

19/12/2013IntegraGen carries out the sequencing of more than one hundred breast cancer metastases, and a French team presents its results.
29/10/2013IntegraGen announces the results of a study on a new version of the ARISk® test to identify the risk of autism in cases of suspected or delayed development.
22/10/20131st half 2013 results
14/10/2013Netastatic colorectal cancer: Exclusive license
29/09/2013Continuous quotation of IntegraGen shares
08/07/2013First-half 2013 sales
08/07/2013Liquidity contract for H1 2013
07/07/2013Publication of a joint study by Inserm, La Ligue and Integragen: "Gastroenterology journal".
01/07/2013Capital increase
15/04/20132012 annual results
08/01/2013Half-yearly report on the liquidity contract

2012

28/11/2012Autism: Results of a parental survey
29/10/20121st half 2012 results
11/07/2012Half-yearly report on the liquidity contract
10/07/2012Successful reserved capital increase
29/05/2012IntegraGen - 57 new genetic markers linked to autism identified
23/04/2012IntegraGen - 2011 Annual Results
05/04/2012IntegraGen launches ARISk™ test in the US, a genetic tool for autism risk assessment
14/03/2012Launch of a study in the United States to develop a genetic test for earlier diagnosis of autism
06/03/2012Very strong sales growth for 2011
06/01/2012Half-yearly report on the liquidity contract
en_US
en_US fr_FR